AI Article Synopsis
- Bipolar disorder (BD) and borderline personality disorder (BPD) are serious mental health conditions that often occur together and increase the risk of substance use disorders (SUD).
- In a study of 3,651 psychiatric patients, those diagnosed with both BD (Type I or II) and BPD had a significantly higher rate of SUD (76%) compared to those with only BDII (50%).
- The findings highlight the need to consider both disorders together in treatment, as their co-occurrence significantly heightens the risk of developing a substance use problem.
Article Abstract
Bipolar disorder (BD) and borderline personality disorder (BPD) are disabling and life-threatening conditions. Both disorders share relevant comorbidities, particularly the risk of having a lifetime substance use disorder (SUD). We tested the hypothesis that patients with both BD type I (BDI) or II (BDII) and BPD would have a higher rate of SUD than would patients with either disorder alone. A total of 3651 psychiatric patients were evaluated with semistructured diagnostic interviews for Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, axis I and II disorders. A total of 63 patients were diagnosed with both BD and BPD, and these patients were significantly more likely to have a SUD compared with BDII patients without BPD (76% vs. 50%, χ = 9.69, p < 0.01). There were no differences when comparing the comorbid group with BPD patients without BD (76% vs. 71%, χ = 0.519, p = 0.4). The present study shows the importance of taking both BPD and BD into consideration insofar as the co-occurrence of the disorders increased the risk of having a SUD especially when compared with BDII alone.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/NMD.0000000000000235 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Neurodiversity Framework in Medicine: On the Spectrum.
Dev Neurobiol
January 2025
Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, Massachusetts, USA.
The term "neurodiversity" refers to the natural heterogeneity in human neurological functioning, which includes neurodevelopmental differences and other mental health conditions (e.g., autism spectrum disorder [ASD], attention-deficit hyperactivity disorder [ADHD], dyslexia, bipolar disorder, schizophrenia, and depression).
View Article and Find Full Text PDFAbnormal network homogeneity in patients with bipolar disorder in attention network.
Brain Imaging Behav
January 2025
Key Laboratory of Adolescent Cyberpsychology and Behavior (Ministry of Education), Wuhan, China.
Bipolar disorder (BD) is a complex psychiatric condition marked by significant mood fluctuations that deeply affect quality of life. Understanding the neural mechanisms underlying BD is critical for improving diagnostic accuracy and developing more effective treatments. This study utilized resting-state functional magnetic resonance imaging (rs-fMRI) to investigate functional connectivity within the ventral and dorsal attention networks in 52 patients with BD and 51 healthy controls.
View Article and Find Full Text PDFThe Effectiveness of Short-Term Group Psychoeducation for Patients With Bipolar Disorder in Japan.
Cureus
December 2024
Department of Psychiatry, Tokyo Women's Medical University, Tokyo, JPN.
Introduction Psychoeducation is a form of psychosocial treatment with proven efficacy in preventing the relapse of bipolar disorder (BD). However, the effectiveness of psychoeducation has not been verified in Japan. We aimed to examine the effect of a brief group psychoeducation course (eight-session long) on relapse prevention in Japanese patients with BD and associated factors.
View Article and Find Full Text PDFImpact of cariprazine on body weight and blood pressure among adults with bipolar I disorder, schizophrenia, or major depressive disorder in a real-world setting.
Ann Gen Psychiatry
January 2025
AbbVie, North Chicago, IL, USA.
Background: Atypical antipsychotics are a common treatment for serious mental illness, but many are associated with adverse effects, including weight gain and cardiovascular issues, and real-world experience may differ from clinical trial data. Cariprazine has previously demonstrated a favorable safety and tolerability profile in clinical trials. Here, we evaluated the effects of cariprazine on body weight and blood pressure for bipolar I disorder (BP-I), schizophrenia, or as adjunctive treatment for major depressive disorder (MDD) using real-world data.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!